Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative ColitisEdo Savelkoul, Frank Hoentjen, Pepijn W. A. Thomas et al.|Inflammatory Bowel Diseases|2022Cited by 47
Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel diseaseMichiel E. de Jong, Maurice G. Rüssel, Erik Taal et al.|Scandinavian Journal of Gastroenterology|2020Cited by 36
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM RegistryFrank Hoentjen, Eline L. Giraud, Pepijn W. A. Thomas et al.|Drug Safety|2021Cited by 20
Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapyPepijn W. A. Thomas, Frank Hoentjen, Jette A. van Lint et al.|United European Gastroenterology Journal|2021Cited by 16
Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort studyPepijn W. A. Thomas, Mark van Caem, Rachel West et al.|European Journal of Gastroenterology & Hepatology|2022Cited by 14